Skip to main content

Table 4 ORs and 95% CIs for HPV-16/E6-83V or E6-83L positive ICC according to HLA

From: Interaction between polymorphisms of the Human Leukocyte Antigen and HPV-16 Variants on the risk of invasive cervical cancer

 

Controls

E6 83V Cases

E6 83L Cases

HLA

C/N

C/N

Crude

Adjusted

C/N

Crude

Adjusted

 

Controls

Cases

OR

OR (95% CI)

Cases

OR

OR (95% CI)

 

n = 257

n = 40

  

n = 29

  

DQA1

       

*0101/04

79/178

7/33

0.48

0.46 (0.19–1.11)

10/19

1.19

1.13 (0.48–2.64)

*0102

80/177

10/30

0.74

0.74 (0.33–1.63)

14/15

2.07

2.24 (0.99–5.09)

DQB1

       

*0301

78/179

11/29

0.87

0.88 (0.40–1.90)

11/18

1.40

1.29 (0.56–3.00)

   *05

95/162

7/33

0.36

0.37 (0.15–0.89)

11/18

1.04

1.08 (0.47–2.49)

*0501

71/186

6/34

0.46

0.44 (0.17–1.14)

9/20

1.18

1.17 (0.48–2.81)

   *06

87/170

16/24

1.30

1.29 (0.64–2.63)

14/15

1.82

1.93 (0.85–4.35)

*0602

44/213

9/31

1.41

1.31 (0.56–3.03)

10/19

2.55

2.33 (0.97–5.57)

DRB1

       

   *01

52/205

6/34

0.70

0.65 (0.25–1.09)

8/21

1.50

1.35 (0.54–3.39)

*0102

29/228

2/38

0.41

0.36 (0.08–1.66)

6/23

2.05

1.70 (0.60–4.82)

   *04

74/183

12/28

1.06

1.11 (0.52–2.37)

3/26

0.29

0.27 (0.08–0.96)

   *13

61/196

9/31

0.93

1.08 (0.47–2.47)

5/24

0.67

0.86(0.30–2.43)

*1302

27/230

0/40

0.00

 

3/26

0.98

1.32 (0.35–4.94)

   *15

34/223

10/30

2.19

2.10 (0.91–4.86)

9/20

2.95

2.78 (1.11–6.92)

*1503

14/243

5/35

2.48

2.40 (0.77–7.51)

5/24

3.62

3.87 (1.20–12.52)

DRB1-DQB1 haplotypes

       

   0102-0501

29/228

2/38

0.41

0.36 (0.08–1.66)

6/23

2.05

1.70 (0.60–4.82)

   15-0602

33/224

8/32

1.70

1.67 (0.68–4.07)

9/20

3.06

2.86 (1.14–7.16)

   1503-0602

14/243

5/35

2.48

2.40 (0.77–7.51)

5/24

3.62

3.87 (1.20–12.52)

   08041-0301

5/252

0/40

  

3/26

5.82

4.10 (0.68–24.81)

   09012-0201/02

3/254

1/39

2.18

2.37 (0.22–25.12)

2/27

6.27

9.36 (1.38–63.25)